Drug Profile
ICT03 Es5
Alternative Names: Es5; ICT03-Es5Latest Information Update: 15 Sep 2023
Price :
$50
*
At a glance
- Originator University of Salford
- Developer Incanthera
- Class
- Mechanism of Action DNA cross linking agents
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Breast cancer; Liver cancer; Non-small cell lung cancer
Most Recent Events
- 15 Sep 2023 Preclinical development is ongoing in Breast cancer in UK
- 15 Sep 2023 Preclinical development is ongoing in Liver cancer in UK
- 15 Sep 2023 Preclinical development is ongoing in Non small cell lung cancer in UK